Coherus Oncology, Inc. — Form 10-Q
Filed August 5, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 8/100
What the filing says
Dennis M. Lanfear (CEO) and Bryan McMichael (CFO) certified on August 5, 2026 that the Q2 2026 10-Q for Coherus Oncology fairly presents financial condition and results of operations, and that disclosure controls and internal controls over financial reporting are effective. No material weaknesses, deficiencies, or fraud were disclosed. This is standard Sarbanes-Oxley certification required for all public companies.
Why this rating
Routine SOX 302/906 certification exhibits with no disclosed control defects or fraud. Boilerplate filing requirement, not a business event.
See more from August 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.